Status:
COMPLETED
Modafinil Effects on Cognition in Schizophrenia Patients
Lead Sponsor:
University of California, Los Angeles
Conditions:
Schizophrenia
Eligibility:
All Genders
18-54 years
Phase:
PHASE4
Brief Summary
Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language. These problems may ...
Detailed Description
Schizophrenia is a disorder of cognition. The cognitive deficits of schizophrenia are present at the onset of the disorder, prior to medication exposure, are persistent during periods of remission, an...
Eligibility Criteria
Inclusion
- adults age 18-54
- diagnosis of schizophrenia or schizoaffective disorder, or healthy with no personal or family history of mental illness
- able to provide informed consent
Exclusion
- history of significant head injury or other neurological illness
- active psychiatric illness requiring significant acute care
- significant intellectual impairment (e.g. standardized full-scale IQ \< 70)
- history of medical illness or treatment that is associated with significant increase in risk from modafinil treatment (e.g. cardiac disease)
- significant active substance abuse
- active pregnancy
- active treatment with medications that have drug interactions with modafinil
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00711464
Start Date
May 1 2008
End Date
July 1 2012
Last Update
September 29 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90024
2
University of California, Davis School of Medicine
Sacramento, California, United States, 95817